Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
Eli Lilly Cuts Sales Outlook After Sluggish Growth for Incretin Drugs
Eli Lilly Cuts Sales Outlook After Sluggish Growth for Incretin Drugs · The Wall Street Journal

In This Article:

Eli Lilly cut its outlook for fourth-quarter revenue citing sluggish growth in the market for incretin, which increases insulin levels.